Skip to main content

Menu

Agilio: Diagnosis and Treatment Guidance July 2025 Update

This update contains 5 significant changes, 7 minor changes and 1 new topic.

Significant Changes:

  • Corticosteroids – oral — reviewed. A literature search was conducted in May 2025 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last version of this topic. No major changes to recommendations have been made.
  • Hand foot and mouth disease — reviewed.  A literature search was conducted in April 2025 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. There have been minor structural changes to the topic, and changes to the recommendations have been updated in line with updated literature. A recommendation to consider the use of topical oromucosal antiseptics or anaesthetics has been added to the management advice section.
  • Hepatitis C — reviewed. A literature search was conducted in May 2025 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic.
  • Immunizations – seasonal influenza — reviewed. The management section has been updated to align with the NHS immunisation programme 2025 to 2026.
  • Jaundice in the newborn — reviewed. A literature search was conducted in April to May 2025 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone minor restructuring. No major changes to the recommendations have been made.

 

Minor Changes:

  • Constipation in children — minor update. Further information on macrogols available for the treatment of constipation added.
  • Gonorrhoea — minor update. Information on diagnosis and treatment of gonorrhoea has been updated in line with updates to the BASHH national guideline for the Management of Infection with Neisseria gonorrhoea BASHH, 2025. This includes the recommendation that pharyngeal testing is recommended for all individuals with urogenital gonorrhoea, first line antibiotic choice, cefixime dosing, and that routine test of cure is not necessary for anogenital infections treated with ceftriaxone1g if the infection is susceptible to ceftriaxone.
  • LUTS in men — minor update. Added information about the potential treatment option of vibegron for voiding or storage symptoms if antimuscarinic medicines are unsuitable, ineffective, or not tolerated. This is based on the National Institute for Health and Care Excellence (NICE) technology appraisal Vibegron for treating symptoms of overactive bladder syndrome NICE, 2024.
  • Neuropathic pain — minor update. Added addiction as a potential adverse effect of pregabalin and gabapentin.
  • Pre-conception – advice and management — minor update. Added information relating to GLP-1 agonists and pre-conception advice.
  • Prostate cancer — minor update. Typographical error in PSA table corrected and a broken link replaced.
  • Restless legs syndrome — minor update. Text about vitamin C has been removed from this topic.

New Topic:

  • Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)